Sec Form 4 Filing - Cheung Wilson Wai-Shun @ SCICLONE PHARMACEUTICALS INC - 2016-08-12

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Cheung Wilson Wai-Shun 2. Issuer Name and Ticker or Trading Symbol SCICLONE PHARMACEUTICALS INC [ SCLN] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CFO & Senior VP, Finance (Last) (First) (Middle) 950 TOWER LANE, SUITE 900 3. Date of Earliest Transaction (MM/DD/YY) 08/12/2016 (Street) FOSTER CITY, CA94404 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 08/12/2016 M 25,000 A $ 0 25,000 D Common Stock 08/12/2016 M 12,500 A $ 0 37,500 D Common Stock 08/12/2016 M 3,000 A $ 0 40,500 D Common Stock 08/12/2016 F( 1 ) 9,396 D $ 10.41 31,104 D Common Stock 08/12/2016 F( 1 ) 1,128 D $ 10.41 29,976 D Common Stock 08/12/2016 F( 1 ) 4,698 D $ 10.41 25,278 D Common Stock 08/16/2016 S 7,802 D $ 10.6174 17,476 D

Table II - Derivative Securities A cquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Restricted Stock Unit ( 2 ) ( 3 ) 08/12/2016 A 30,000 ( 4 ) ( 4 ) Common Stock 30,000 $ 0 229,000 D Restricted Stock Unit ( 5 ) ( 3 ) 08/12/2016 M 25,000 ( 6 ) ( 6 ) Common Stock 25,000 $ 0 204,000 D Restricted Stock Unit ( 5 ) ( 3 ) 08/12/2016 M 12,500 ( 7 ) ( 7 ) Common Stock 12,500 $ 0 191,500 D Restricted Stock Unit ( 5 ) ( 3 ) 08/12/2016 M 3,000 ( 8 ) ( 8 ) Common Stock 3,000 $ 0 188,500 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Cheung Wilson Wai-Shun 950 TOWER LANE, SUITE 900 FOSTER CITY, CA94404 CFO & Senior VP, Finance Signatures /s/ Wilson W. Cheung 08/16/2016 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Shares disposed represent shares withheld to cover withholding tax obligations in connection with the vesting of Restricted Stock Units. ( 2 )Granted under the Issuer's 2015 Equity Incentive Plan. ( 3 )Each restricted stock unit represents the contingent right to receive one share of SciClone Pharmaceuticals, Inc.'s common stock. ( 4 )Each RSU will vest and be settled on August 15, 2017, subject to the reporting person's continued employment, but will terminate upon the occurrence of a change in control on or before March 31, 2017. ( 5 )Granted under the Issuer's 2005 Equity Incentive Plan. ( 6 )Provided Reporting Person remains employed by the Issuer, 33.33% of the restricted stock units vested on January 4, 2016, 33.33% will vest on January 3,2017, and 33.34% will vest on January 2, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open. ( 7 )Provided Reporting Person remains employed by the Issuer, 25% of the restricted stock units will vest on each August 9, 2014, August 9, 2015, August 9, 2016, and August 9, 2017, unless the trading window is closed for the Reporting Person on such date, in which case the vesting date will be deferred until the next date that the trading window is open. ( 8 )Vesting for such RSUs will occur 25% on March 16, 2016, 25% on March 16, 2017, 25% on March 16, 2018, and 25% on March 16, 2019, or on such later date thereafter as the Company's trading window opens, if it is not open on any of such dates, contingent upon the executive's continued employment.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.